Literature DB >> 22226332

The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.

Rachel L Berkowitz1, Urvashi Patel, Quanhong Ni, Joseph J Parks, John P Docherty.   

Abstract

BACKGROUND: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a series of effectiveness trials. The results of these trials began publication in September 2005. Among other findings, these studies were interpreted to suggest that (1) second-generation antipsychotics might have fewer advantages over first-generation antipsychotics than had been generally thought; (2) among the agents assessed, olanzapine had the best efficacy outcome; and (3) after treatment failure with a second-generation antipsychotic, the most efficacious second-line medication is clozapine. To examine the actual impact on practice of these publications, we looked at change in physician prescribing behavior based on these 3 conclusions before and after publication of CATIE.
METHOD: Rates of antipsychotic medication prescriptions to 51,459 patients with an ICD-9 code of 295 for schizophrenia were extracted from a Missouri Medicaid claims database. χ² Tests were used to compare the rates of prescribing antipsychotic medications before and after each of 3 key CATIE publications (time 1 was September 2005, time 2 was December 2006, and time 3 was April 2006).
RESULTS: At all time points, we demonstrated a decrease in prescriptions by all prescribers for olanzapine (P < .0001). One year after time 1, we found an increase in prescriptions by all prescribers for aripiprazole (P < .0001). No statistically significant increases in clozapine prescribing were observed. Also, a small but statistically significant increase was seen in prescriptions of perphenazine (P < .02 at time 3). However, this increase occurred only for prescriptions written by psychiatrists and not other prescribers.
CONCLUSIONS: We found some evidence in our sample that the publication of the results from CATIE had a small but statistically significant effect on prescribing habits of psychiatrists but not other physicians in our sample population. However, larger changes occurred in prescribing behavior that were largely unrelated to the CATIE trial. We propose a hypothesis to explain the direction of observed changes. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22226332     DOI: 10.4088/JCP.10m06497

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.

Authors:  Madeline M Corrao; Leigh Anne Nelson
Journal:  CNS Drugs       Date:  2022-05-30       Impact factor: 6.497

2.  Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.

Authors:  Derek K Tracy; Dan W Joyce; S Neil Sarkar; Maria-Jesus Mateos Fernandez; Sukhwinder S Shergill
Journal:  BMC Psychiatry       Date:  2015-07-25       Impact factor: 3.630

3.  Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Authors:  Brian Godman; Max Petzold; Kathleen Bennett; Marion Bennie; Anna Bucsics; Alexander E Finlayson; Andrew Martin; Marie Persson; Jutta Piessnegger; Emanuel Raschi; Steven Simoens; Corinne Zara; Corrado Barbui
Journal:  BMC Med       Date:  2014-06-13       Impact factor: 8.775

4.  Realising stratified psychiatry using multidimensional signatures and trajectories.

Authors:  Dan W Joyce; Angie A Kehagia; Derek K Tracy; Jessica Proctor; Sukhwinder S Shergill
Journal:  J Transl Med       Date:  2017-01-18       Impact factor: 5.531

5.  Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.

Authors:  Frederico G S Toledo; William F Martin; Linda Morrow; Carine Beysen; Daiva Bajorunas; Ying Jiang; Bernard L Silverman; David McDonnell; Mark N Namchuk; John W Newcomer; Christine Graham
Journal:  Neuropsychopharmacology       Date:  2021-12-09       Impact factor: 7.853

6.  Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.

Authors:  Amber Martin; Leona Bessonova; Rachel Hughes; Michael J Doane; Amy K O'Sullivan; Kassandra Snook; Allie Cichewicz; Peter J Weiden; Philip D Harvey
Journal:  Adv Ther       Date:  2022-07-18       Impact factor: 4.070

7.  Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Authors:  Brian Godman; Anna Bucsics; Thomas Burkhardt; Jutta Piessnegger; Manuela Schmitzer; Corrado Barbui; Emanuel Raschi; Marion Bennie; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-01-07       Impact factor: 5.810

8.  Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.

Authors:  Lei Sun; Richard Mills; Brian M Sadler; Bhaskar Rege
Journal:  J Clin Pharmacol       Date:  2021-08-04       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.